Randox Testing Services: Customer Testimonials from Ireland
Randox Testing Services: Customer Testimonials from Ireland
At Randox Testing Services (RTS), we pride ourselves on helping our customers improve the health and safety of their working environment. Using our accurate and reliable testing methods and a range of additional services including training and policy reviews, we create tailored packages to meet the needs of our customers. We work with customers all over the world, but this month are highlighting the work we are doing across Ireland.
This month RTS will be attending the Northern Ireland Occupational Health, Hygiene and Wellbeing Conference at Titanic Belfast. This conference brings together companies from a range of industries all across Ireland to discuss the importance of employee health and wellbeing. As a company that began in Northern Ireland, RTS have always had strong connections with local businesses and are continually expanding our reach across Ireland.
Some of the companies with which we currently work, like GRAHAM construction, have recently provided feedback on our services. GRAHAM is based in Hillsborough, Co. Down and is a national construction, asset management and project investment business. They deliver services to a diverse range of clients from a network of regional offices, throughout the UK and Ireland.
“GRAHAM Construction are proud to be partnered with Randox as their main Drug & Alcohol Service Provider. Over the years they have given a consistent, prompt, efficient, and professional service that delivered what was promised, when promised, to the proper agreed standards, which assists us in managing our relevant responsibilities with ease and confidence. I would have no hesitation in recommending them to others.”
This is great feedback to receive from such a reputable company who have a range of different testing needs. The construction industry is becoming more and more proactive when it comes to drug and alcohol testing. At RTS our experience working with GRAHAM and other major construction firms across the UK and Ireland means we are extremely well equipped to deal with the changing needs of this industry.
Another industry which requires a flexible and reliable drug and alcohol testing services provider is the aviation industry, especially when it comes to recruitment. We have been working with CAE Parc Aviation Services, the global leader in the provision of aviation personnel and support services to conduct pre-employment testing.
“We use Randox for Pre-Employment and Random Drug & Alcohol testing for select clients. We would happily recommend their services.”
Again, through working with various industries, the experience our staff possess is second to none. By qualifying the exact needs of our customers we create customised, cost-effective packages to ensure all testing needs are met.
As well as offering drug and alcohol testing services, our complete solution also includes a host of training, educational and consultancy services to equip our customers in tackling drug and alcohol misuse. Including comprehensive chain of custody training programs, which enables employers to conduct on-site collections to the same standard as a Randox Testing Services collection specialist.
The Henderson Group in Newtownabbey are another large company that has availed of the services offered by Randox Testing Services. The Henderson Group are the owners of the SPAR, EUROSPAR, ViVO, ViVOXTRA and ViVO Essentials franchises in Northern Ireland and have been distributing food and grocery-related products to the convenience retail sector for over 100 years.
“We switched provider for our Drug and Alcohol policy almost two years ago, moving to Randox. The switchover was relatively seamless and the impact on our business has been positive. Our tests are now all completed within target and we have realised a saving to boot. We are glad we made the switch.”
Randox Testing Services is committed to tailoring our service to the needs of customers all over the world, and across the island of Ireland.
If your company would like to speak to us, please contact testingservices@randox.com
Alternatively you can contact David O’Regan, the Business Development Executive for Ireland directly: David.O’Regan@randox.com.
Understanding your heart health with Randox Health
Today in the UK, on average, 530 people will be admitted to hospital with a heart attack – even though 75% of heart disease is preventable.
Why wait?
At Randox Health, we believe in preventing disease, instead of waiting for it to occur. We do this through our comprehensive health checks, which use innovative Randox technology to provide you with up to 350 test results, covering over 25 different areas within the body. One of those areas is the heart, by using our ‘Heart Health test panel’. This panel offers up to 21 tests, including a cardiovascular risk score, which assesses your risk of developing cardiovascular disease over the next 10 years.
Our Heart Health panel also measures apolipoproteins, which are proteins which bind cholesterol for transport around the body. Measuring apolipoproteins along with traditional cholesterol markers, such as LDL (bad) cholesterol and HDL (good) cholesterol, gives us a much more detailed understanding of your Heart Health, compared to using traditional cholesterol levels alone. A unique test in our panel can identify damage to heart muscle, which can occur with a heart attack.
It’s in the genes
As well as our comprehensive Heart Health panel, offered within our programmes, Randox Health also offer more specialised cardiac testing.
Taking cardiac risk assessment one step further, our Cardiac Risk Prediction testing can predict your risk of coronary heart disease (CHD) using not only traditional cholesterol and blood pressure measurements, but using advanced genetic testing. Such testing will combine various genetic tests known to be associated with increased risk of CHD, along with measurements such as blood pressure and cholesterol to calculate and provide you with an overall CHD risk score.
If you have high cholesterol, or heart disease runs in your family, you may benefit from our Familial Hypercholesterolaemia (FH) genetic screen. FH is a hereditary condition involving high cholesterol levels and a high risk of having a heart attack or stroke at a younger age. FH occurs in approximately 1 in every 250 people worldwide and it is thought that 90% of individuals with the condition remain undiagnosed! At Randox Health we recognise the importance of detecting this condition as early as possible; therefore, we offer testing which can check simultaneously for several genetic mutations known to be involved in FH. Early diagnosis and treatment of FH significantly improves and lengthens the lives of those affected, as well as saving the lives of their beloved family members.
To find out more, click here or call 0800 2545 130 and one of our team will be able to discuss this in more detail with you.
We are attending Bee Happy Bulgaria 2018 on 1st ā 4th March!
Bees and other pollinators are vital to three-quarters of the world’s food crops but have been in serious decline in recent decades. The destruction of wild habitats, disease and widespread pesticide use are all important factors.
Global honey production is projected to reach 2.4 million tons by 2022 this is driven by a growth in consumers demand for a natural and healthy alternative to artificial sweeteners, a rising awareness over the benefits of using honey as a sweetener over cane sugar and the realisation of the antibacterial and inflammatory properties of manuka honey.
The decline in the numbers of bees and rising demand from consumers for natural honey products has created a market for “illegal honey” being produced to supply the demand. Producers ‘cut’ their honey with additives like high-fructose corn syrup and brand it as natural honey, affecting purity and reducing cost.
‘Honey laundering’ has also become an issue, with countries such as China using non FDA approved chemicals within beekeeping and being non-compliant to regulations causing their honey to be banned from entering the USA. To get around this, Chinese honey is being shipped into countries such as Vietnam where it is then re labelled and moved into the USA with a new country of origin on the label. This has created the need for a reliable and accurate way to test honey globally.
In order to help the industry Randox Food Diagnostics developed the Evidence Investigator analyser. The Investigator uses Biochip Array Technology (BAT), a technology that was developed by Randox, to detect multiple residues (up to 45) from a single sample. Tests for honey include a vast range of antimicrobials such as Quinolones, Streptomycin, Chloramphenicol, Nitrofurans and more. Randox Food Diagnostics are also releasing a pesticides array in early 2018. Also offered are a range of ELISA test kits.
Alongside the evidence Investigator Randox Food Diagnostics developed the RX misano for enzymatic analysis of honey. The RX misano is now available for the analysis of diastase, total sugars (glucose/fructose), HMF (hydroxymethylfurfural) & colouration, with sucrose coming in 2018.
Randox Food Diagnostics will be attending Bee Happy Expo in Bulgaria from 1st – 4th March 2018 Stop by booth 25 or catch our presentation on Saturday 3rd March at 14:30 to learn more about our product offering for honey.
For more information visit the Randox Food Diagnostics website at: http://www.randoxfood.com/matrices/honey
Or email: info@randoxfooddiagnostics.com
Take a proactive approach to your kidney health this World Kidney Day
On 8th March 2018, it’s World Kidney Day, a global campaign aimed at raising awareness of the importance of good kidney health. With a similar agenda to that of Randox, whose vision it is to ensure patients across the globe have access to the latest advancements in health technology, World Kidney Day works to reduce the frequency and impact of kidney disease and its associated health problems.
This year, the World Kidney Day theme is Kidneys and Women’s Health, to highlight that approximately 195 million women worldwide are affected by Chronic Kidney Disease. In 2018 World Kidney Day and International Women’s Day are recognised on the same date, offering the perfect opportunity to reflect on the importance of women’s health and specifically their kidney health.
CKD is currently the 8th leading cause of death in women, with close to 600,000 deaths each year.
According to some studies, CKD is more likely to develop in women compared with men, with an average 14% prevalence in women compared to 12% in men.
However, the number of women successfully put on dialysis for their Chronic Kidney Disease is lower than the number of men – potentially due to slower progression of the disease, inequitable access to transplantation, and a general lower disease awareness.
It is therefore fitting that World Kidney Day has chosen Women’s Health as its theme for this year – due to the clear need for a higher awareness, timely diagnosis and proper follow up of kidney issues amongst women.
With a comprehensive panel of kidney health tests, Randox are working to ensure timely diagnosis of kidney function problems, to ensure that necessary treatment is administered at the earliest possible stage, when it is most likely to be successful.
For example, the Randox test for albumin, low concentrations of which are the earliest marker of kidney damage, can identify individuals with diabetic nephropathy (damage to the kidneys caused by diabetes) around 10 years earlier than standard protein tests. The Randox albumin test can therefore enable preventative measures to be taken to reduce your risk of developing kidney disease.
In addition to albumin, there are a number of other highly specific and sensitive tests for kidney health, which are available as part of a Randox Health Check at our Randox Health Clinics. These include;
- Estimated Glomerular Filtration Rate, which is an equation that considers age, gender, blood and protein levels to determine how well the kidneys are functioning.
- Creatinine, which is a waste product produced by muscle tissue, and removed by the kidneys. When kidney function is diminished, creatinine levels increase.
- Other proteins within the body which should be filtered by the kidneys, and are therefore measured to determine kidney function, include;
- Cystatin C
- Beta-2-Microglobulin
- Microalbumin, which is not usually found in urine, but can appear when normal kidney function is impaired.
- Minerals processed by the kidneys and analysed by Randox Health include;
- Magnesium
- Calcium
- Phosphate
- Potassium
- Sodium
Both World Kidney Day and Randox are working towards improving healthcare worldwide. With access to these high-performance kidney health tests, patients with kidney problems can be diagnosed early, before the condition develops into something more serious.
Although end stage kidney failure affects only 0.05% of the general population, it commands between one and two billion pounds a year of the entire annual NHS budget. We know that loss of kidney function is devastating and hope our innovations can identify those at risk of kidney problems before they occur.
One such test for Chronic Kidney Disease risk measures levels of the protective hormone adiponectin, and is available exclusively at Randox.
Adiponectin can accurately assess levels of hidden and dangerous visceral fat within the body, which is the main cause of almost all the disorders associated with metabolic syndrome, including Chronic Kidney Disease. Assessing adiponectin can determine risk of CKD, as well as a range of other illnesses including prediabetes, cardiovascular disease and various cancers.
By using adiponectin to assess risk of kidney problems, we can empower individuals with the tools they need to prevent kidney problems in their future.
With early diagnosis we can improve patient treatment outcomes and reduce the number of people across the world suffering with kidney health problems.
If you are a clinician or lab interested in running renal function assays, download our Reagents Brochure or email reagents@randox.com
If you want to find out the status of your own Kidney Health, book a health check with Randox Health today. Speak to our team by phoning 0800 2545 130.
Randox Teoranta announce fourth year of WAAR sponsorship
Randox are proud to announce that Randox Teoranta, for the fourth year running, is the main sponsor for WAAR 2018, an event which places mental wellbeing at its core. Launched at the weekend, on Friday 23rd February 2018, this year’s Wild Atlantic Adventure Race promises to deliver an incredible display of stamina, strength and perseverance as outdoor pursuit enthusiasts once again brave the elements to complete the demanding 55.5km course or 39km sprint.
The full Wild Atlantic Adventure Race (WAAR) features a 10km run, 42.5km cycle, 2km hike and 1km kayak, starting and finishing at CLG Naomh Muire, The Banks, Mullaghderg, Co. Donegal on Saturday 12th May 2018. Set along one of the most beautiful natural coastlines in the world, the west coast will once again play host to one of the most challenging yet enjoyable races, featuring both novice and elite individuals, as well as several relay teams.
This year, fundraising efforts will be donated to CLG Naomh Muire. Launching the event was best-selling author and TV personality Majella O’Donnell who overcame breast cancer in 2013.
Hailing from Co. Tipperary and married to Irish country music legend Daniel O’Donnell, Majella became iconic in her own right when she shaved her head live on The Late Late Show in 2013, raising €600,000 for The Irish Cancer Society. Majella also documented her life story in her book ‘It’s All in the Head.’ The book’s moving tale quickly became a number one Irish best-seller and 2014 Irish Book Award-winner.
Majella’s own force of character and deep-seated determination makes her a worthy representative to launch WAAR 2018, an endurance race that will test the physical and mental stamina of participants to their limits.
Dr. Ciaran Richardson, Head of Research & Development at Randox Teoranta in Dungloe, said:
“We are delighted to, once again, partner with WAAR. The event is a real test of physical wellbeing and here at Randox, we take our on-going work to promote positive physical and mental health very seriously. In the last few years, our labs in Dungloe have led the way in world-leading diagnostic research in a wide range of areas including Alzheimer’s disease, kidney disease, cancer, gastrointestinal disorders and stroke.
The WAAR launch was a great success and we look forward to the exciting event in May. We encourage as many people as possible to get involved as it’s sure to be another thrilling event for both entrants and spectators alike.”
For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com
Ā£50m Randox Centres of Excellence launched in Northern Ireland
A record £50 million investment which will deliver cutting-edge technologies to diagnose conditions like cancer, heart conditions and infectious diseases has been announced by Northern Ireland diagnostics company Randox Laboratories and Invest Northern Ireland.
This major project involves the establishment of three Centres of Excellence, enabling Randox R&D scientists to work collaboratively with colleagues from Queen’s University Belfast and Ulster University. The centres are being officially launched today at the Randox Science Park. The ceremony will include a keynote address from Sir John Bell, who chaired the UK Government’s Life Sciences Industrial Strategy Board.
Advanced diagnostics have been identified as key to delivering sustainable improvement to healthcare systems struggling to cope with increasing levels of chronic and preventable conditions. Having been focused in this field for over 36 years, Randox has a successful track record of developing new and innovative tests – examples include assessing those at risk of Alzheimer’s disease and genetic cardiac conditions, to promote and enable preventive treatment, and a new clinically-approved test to diagnose prediabetes.
Managing Director of Randox Laboratories, Dr Peter FitzGerald, who today launched the three Centres of Excellence, said;
“When almost a quarter of the deaths of people under 75 in the UK are considered preventable, we need to ask ourselves what can be done to improve healthcare outcomes. There is an undeniable case for radical change in the way healthcare is delivered, and sophisticated diagnostics will be at the fore of this revolution.
“Enabling earlier and more accurate diagnosis, to identify those at the earliest stages of illness, ideally before the onset of any symptoms, is a game-changer. Through early intervention we can restrict the development of chronic conditions and improve people’s lives. Our view of the future is one where people are empowered through earlier diagnosis to stay healthier for longer, and where healthcare systems are freed to deliver quality services to patients. Our announcement today demonstrates our continuing commitment in this field.
“We are grateful for the support offered by Invest NI and look forward to addressing these pressing healthcare needs.”
The Centres of Excellence will focus respectively on clinical diagnostics, engineering for biosciences and quality control. The project, which will strengthen collaborative partnerships between Randox, Queen’s University Belfast and Ulster University, will accelerate the development of new technologies and drive healthcare improvements regionally, nationally and across the globe.
Of the £23m of support offered by Invest NI, £5m will go toward research projects at Ulster University and Queen’s University Belfast.
Welcoming the investment, Alastair Hamilton, Chief Executive of Invest NI said;
“Randox has a long history of investing heavily in innovation and R&D which has enabled it to create a globally competitive export driven business, capable of developing world leading research. This major investment will enable Randox to perform cutting-edge R&D which has the potential to revolutionise the global healthcare industry. This is excellent news for Northern Ireland’s life and health sciences sector. Northern Ireland is enjoying a growing international reputation as a region of expertise and knowledge in key areas such as Diagnostics, Precision Medicine and Advanced Manufacturing. The three new Centres of Excellence will help build on this and enhance Northern Ireland’s credibility, provide supply chain opportunities, and encourage knowledge transfer with our universities.”
Sir John Bell, commenting on the potential for the UK Life Sciences sector said;
“The life sciences industry represents one of the dominant economic sectors in the UK, and one with considerable potential for growth. However, whilst we have many natural strengths we cannot afford to be complacent. We must strive to optimise our science base, to encourage collaboration across academia, industry and the NHS, and grow our industrial capabilities. To do so we need to use our extensive data sets to best effect, and have in place a strong skills strategy. Success requires vision and drive. To that end I would like to congratulate Dr FitzGerald and Randox in the establishment of these three R&D collaborative Centres of Excellence – these are assets of national standing and will have a meaningful impact in enabling earlier and more accurate diagnosis, driving improvements in patient care, regionally, nationally and globally. They are leaders in this field, committed to innovation, and I wish them every success.”
Professor Jim McLaughlin, Director of Ulster University’s Nanotechnology and Integrated Bioengineering Centre, added;
“This very welcome investment enables pioneering Randox-inspired engineering capacity at Ulster University and reflects our research commitment to the life sciences industry. From nanotechnology to the development of systems that will enable large scale laboratory capability to be produced in the palm of your hand, the partnership brings shared industry and academic research excellence from the lab into the marketplace. Life sciences is a vital economic sector locally and this collaboration will advance diagnostics and ultimately enhance patient health outcomes.”
Dr David Jess, Senior Lecturer at Queen’s University Belfast School of Mathematics and Physics, added;
“The Randox Centres of Excellence will allow Queen’s University Belfast to continue to deliver cutting-edge and world leading research. We look forward to collaborating further with industry to develop pioneering research, focused on the needs of society.”
Invest NI’s R&D support is part funded by ERDF under the EU Investment for Growth and Jobs Programme 2014 – 2020.
For further information please contact the Randox PR Team: phone 028 9442 2413 or email randoxpr@randox.com
Evidence MultiSTAT: Fast, Fully Automated and Versatile
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. It requires a small sample volume and generates results in less than 20 minutes. The process from sample entry to results can be completed in 3 simple steps, with minimum room for human error.
The MultiSTAT offers a very simple drug screening solution to those who have no knowledge of laboratory procedures through combining simplicity with cutting-edge innovation. It is this innovative technology that enables the MultiSTAT to be easy to use, yet extremely powerful.
Versatility
Whether testing is needed for new entrants going into prison, or for a drug drive test – the MultiSTAT is adaptable for use across a range of different applications. As an analyser, it can deliver highly accurate and reliable laboratory quality results. Its ability to provide these quickly and over a wide range of substances makes it as flexible as any point of care test. The Evidence MultiSTATs ease of use makes it accessible to all with no previous laboratory experience required.
The Evidence MultiSTAT is a versatile analyser that provides automated drugs screening in a range of settings, such as low throughput laboratories, workplaces and police stations. Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results and offers a highly sensitive way to detect drugs of abuse.
Extensive
The MultiSTAT facilitates on-site simultaneous screening of multiple drug classes, including classical, prescription and synthetic drugs of abuse. Available matrices include oral fluid, with blood and urine coming soon.
Recently, the InfiniPlex for Milk Array has been developed by Randox Food Diagnostics to help the dairy industry improve the global standards of dairy. Complying with 98% of EU regulated antibiotics, InfiniPlex is currently unrivalled in the market with the ability to simultaneously detect anti-parasitics, anti-inflammatories and unauthorised substances found in dairy products from a single sample of raw milk using Biochip Array Technology. With results screened in just under 20 minutes, the Evidence MultiSTAT is ideally suited to the fast-paced nature of the dairy industry.
Developed with the user in mind, no technical expertise is required to use the test and is available on two analysers in the Evidence Series, the Evidence MultiSTAT and Evidence Investigator.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For more information on the Evidence MultiSTAT, or any of the Evidence Series analysers, visit https://www.randox.com/evidence-series/ or contact us evidenceseries@randox.com.
Take control of your heart health with Randox
Your heart is amazing. Not only is it your most critical organ but also one of the most hard-working. The average adult heart beats around 100,000 times a day, acting as a giant pump for all the blood in your body. Indeed, every day your heart pumps over nine litres of blood through a system of blood vessels over 60,000 miles long – it’s little wonder, then, the importance placed on looking after such a vital muscle.
The heart works 24/7, only taking a rest when you sleep with the natural drop of heart rate and blood pressure. Over time, and influenced by lifestyle choices, the heart grows weaker, needing to work harder to fulfil its function. Crucial lifestyle changes now could limit your risk of developing serious cardiac conditions, such as Cardiovascular Disease (CVD) in the future. Factors which can contribute to your CVD risk include genes inherited from parents or grandparents, smoking, an unhealthy diet, excessive alcohol consumption and low physical activity levels.
You can’t change your DNA, but you can find out what it means to you and your family. One of our advanced tests can identify people living with a common but often hidden disorder – Familial Hypercholesterolemia (FH). Fewer than 12% of people in the UK know they have this potentially fatal condition. It is characterised by dangerously high levels of cholesterol which can lead to early onset cardiovascular disease.
While lifestyle changes may help to limit your risk of CVD, and related heart condition, it is impossible to eradicate it completely for everyone. Accounting for 31% of deaths worldwide, CVD is the number one cause of death globally but early screening could lower this figure significantly. That’s why it’s vitally important to detect CVD early before a coronary event like a heart attack occurs.
Today in the UK, 530 people will go to the hospital with a suspected heart attack. Only a fifth of these people will actually be having a heart attack. According to a team from King’s College London, as reported by the BBC, a faster, more accurate diagnosis of whether chest pain is caused by a heart attack would save the health service millions of pounds each year by sending well patients home and freeing up beds. Yet current testing methods do not efficiently differentiate between high-risk patients and the estimated 80% of patients who are not having a heart attack.
Randox’s revolutionary test for Heart-Type Fatty Acid-Binding Protein (H-FABP), when combined with current testing, is able to rule out a heart attack for patients who present at A&E with chest pain which is caused by other conditions such as respiratory issues, meaning they may not need emergency admission.
When measured at the time a patient presents to A&E with chest pain, H-FABP enables doctors to triage patients suffering with a heart attack more efficiently than before, making sure those at high-risk are given medical intervention earlier.
Early screening in the form of a comprehensive health check is essential to detect cardiac irregularities before they become serious problems. Heart damage builds up over time, meaning that when detected early enough, lifestyle changes can help to reduce cardiac risk and potentially even prevent a cardiac event occurring.
Therefore, it is vitally important that individuals are tested for CVD to detect them in the earliest stages to reduce damage, prevent further damage, or even death. Furthermore, many people suffer from inherited cardiac risk factors, which stresses the need for accurate testing.
Randox offer the complete laboratory solution to cardiac risk assessment information to doctors and hospitals, and also directly to the public at Randox Health. Our range of both traditional and novel cardiac risk biomarkers, along with our technologically-advanced range of analysers, serves to allow us to offer the most advanced, most accurate health check available on the planet.
As well as your cardiovascular risk score, a Randox Health check will also assess your cholesterol levels, FH risk, triglycerides, creative kinase, myoglobin, troponin levels and many more heart health indicators. In total, a Randox Health check can assess up to 350 different markers of irregularity or disease in the whole body, from heart to hormone health and skin to stomach.
Many serious future health issues are preventable now with action. Find out more about our health check programmes here.
About Randox Health
Randox Health is a global leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis using Randox products each year.
After investing over £220 million in the invention and production of revolutionary blood-science technology, a single Randox Health check will deliver a complete picture of your health – as it is now and, crucially, how it is likely to develop in the future.
Randox Health has proven that signs of disease or irregularity can be caught at their earliest stage. This means that, with early action, some cases of illness can even be prevented altogether. Our health checks include, but are not limited to, cancer surveillance, fertility monitoring, heart health, nutrition, digestive and diabetes health.
In other words, from one health check, you’ll receive up to 350 results and afterwards avail of expert advice from the Randox scientists or a Randox Health GP. Not only that, but a complete 12-month programme and repeat testing come as standard so you can have full confidence that you are really taking care of yourself.
Find out more information about Randox Health checks here: https://www.randoxhealth.com/our-packages/
RX Series
Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs. For more information on the Randox RX series, please click here or email therxseries@randox.com
Reagents
Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have the largest test menu of 118 assays, covering over 100 disease markers including specific proteins, lipids, therapeutic drug monitoring, drugs of abuse, antioxidants, coagulation, diabetes and veterinary testing. A wide range of formats and methods are available providing greater flexibility and choice for any laboratory size. In addition to flexible pack sizes and a comprehensive list of analyser applications, we can also provide dedicated reagent packs (Randox Easy Read and Easy Fit regents) for a wide range of chemistry analysers providing you with freedom of choice from an independent manufacturer.
For more information on Randox Reagents, please click here or email reagents@randox.com
Acusera – Internal Quality Control
The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control. The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. For more information on the Randox Acusera internal quality control, please click here or email acusera@randox.com
RIQAS – External Quality Control
The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T. RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost. All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience. Submit your results bi-weekly and view reports online via RIQAS.Net. For more information on RIQAS, the world’s largest international EQA scheme, please click here or email acusera@randox.com
For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
Alprazolam and Prescription Drug Abuse
Alprazolam, also known as the trade name Xanax, is a widely prescribed anxiety drug in the US. Alprazolam is a minor tranquilliser which can cause sedation, short term memory loss and depress the nervous system, slowing down the brain and body. Recommended for short term use, the drug can be highly addictive and only be obtained on private prescription in the UK.
People have been known to crush or melt the dangerous tranquilliser that comes in a tablet form, to inject the substance. Extremely dangerous and fatal, the chalk in the tablets can cause collapsed veins and lead to an abscess and infection.
A recent article by BBC News uncovered that Alprazolam is being purchased online and abused by children as young as 13. The news comes after reports of social media sites being used to buy dangerous substances and locate drug dealers. In 2017, up to 20 teenagers from Wiltshire needed treatment after using Alprazolam. This year in Sussex alone, several young people have been admitted to hospital after taking the prescription drug.
A spokesperson from Pfizer, a Xanax manufacturer, expressed concerns over the alarming rise of counterfeit Xanax drugs and the growing availability on the dark web. Discussing the issue, they mentioned that ingredients such as boric acid, heavy metals and floor polish have been found in counterfeit Xanax medications. Defined as “part of our youth culture” Nick Hickmott from Addaction states, it is currently debatable how many people are currently using Alprazolam. London’s MP Bambos Charalambous has called for awareness campaigns and further research to be conducted in order to support services.
Alprazolam is not the only widely abused prescription drug, as criminal gangs were reported smuggling tens of millions of prescription drugs out of the UK’s protected supply chain. Northern Ireland have also expressed concerns over the rise of pregabalin, with BBC spotlight revealing a 46% rise from a data base of 20 million prescription records written by GPs across the country in the past four years. However, the biggest killer in Northern Ireland is tramadol, a prescription painkiller taken by thousands daily.
Randox Toxicology offer the most comprehensive drugs of abuse test menu across multiple forensic matrices. Our level of expertise in toxicology has enabled us to provide the DoA ULTRA panel, which can screen for a wide range of prescription drugs of abuse, including Alprazolam and Tramadol. Using our revolutionary Biochip Array Technology, Randox Toxicology provide a complete immunoassay profile in the initial screening phase.
For more information about our DoA ULTRA panel and how Randox Toxicology are fighting drugs of abuse, email us at info@randoxtoxicology.com
For further information, please contact the Randox PR team via email: randoxpr@randox.com or phone 028 9442 2413
Celebrating Valentine’s Day with the Cardiac Prediction Array from Randox Biosciences
With Valentine’s Day being in the heart of National Heart Month, Randox Biosciences want to take this opportunity to talk about the importance of looking after your heart and the awareness of the tests out there currently on offer.
The British Health Foundation launched National Heart Month with the aim to spread awareness of heart disease and to encourage the nation to make small changes towards a healthier lifestyle.
Currently Coronary Heart Disease (CHD) is the leading cause of death in the UK, with 73,000 people dying from Coronary Heart Disease every year in the UK.1
Coronary Heart Disease is a disease in which plaque builds up inside the coronary arteries. Our arteries supply oxygen-rich blood to the heart muscles, however, over time plaque builds up and can harden. This hardened plaque, then narrows the coronary arteries reducing the flow of oxygen-rich blood to the heart, which can lead to angina or a heart attack to occur.2
CHD is more likely with increasing age, in men rather than in women before menopause and if close relatives have suffered CHD early in life. These risk factors cannot be changed, however, there are other risk factors that can be modified. These are known as elevated blood cholesterol, overweight and obesity, smoking, lack of physical activity, unhealthy diet and stress.
You can prevent and control many CHD risk factors with heart-healthy changes and medication. There is only a few risk factors that can’t be controlled such as your age, gender and family history. Nonetheless, many lifestyle changes help control several CHD risk factors at the same time, such as physical activity which may reduce stress, lower your blood pressure, help control diabetes and help control your weight.
If you believe you are at risk of coronary heart disease, you can ask for a risk assessment for heart diseases, heart attack or stroke. However, current CHD risk assessment tools based on common risk factors such as blood pressure and blood cholesterol levels have low predictive value and take no account of genetic predisposition to CHD.
In recent years, Genome Wide Association Studies (GWAS) have been carried out to identify genetics variants associated with CHD. Meta-analysis of such studies has identified 19 variants as being associated with CHD.
Individually, the presence of an “at risk” variant does not greatly increase the risk of developing CHD. However, the presence of multiple “at risk” alleles can increase the risk of developing CHD two-fold or greater an effect similar to being a current smoker. Combining genotype information with common risk factors could allow individuals to be more accurately classified therefore preventative therapies and lifestyle advice can be targeted to those who require it most.
In order to utilise the GWAS findings within a clinical setting, individuals require to be genotyped for each of the 19 CHD “at risk” SNPs. However, at present this can be a time consuming and expensive process.
Together with key opinion leaders in cardiovascular genetics, Randox has developed the Cardiac Risk Prediction Array which will allow all 19 SNPs to be genotyped simultaneously, which incorporates a test to identify patients predisposed to statin induced myopathy.
Firstly, a multiplex PCR reaction is performed, where the products amplified correspond to the genotype of the patient sample. The PCR products are then hybridised onto the Cardiac Risk Prediction biochip array and imaged using the Evidence Investigator analyser to identify which PCR products are present. Patient samples can be genotyped within 1 day.
This Heart Month, we are urging the pubic to not only help raise awareness of heart disease but also educate themselves on the signs and symptoms to increase early diagnosis. As a global diagnostic company, Randox Biosciences are committed to the ongoing development of diagnostic tests, as well as our research into numerous disease areas to improve health worldwide.
To find out more email us at info@randoxbiosciences.com
Sources
1 – HeartUK
2 – National Heart, Lung and Blood Institute
